FBT - ETF AI Analysis
Top Page
First Trust NYSE Arca Biotechnology Index Fund (FBT)
Rating:71Outperform
Price Target:―
Positive Factors
Healthy Fund Size
The ETF manages a large pool of assets, which can support better liquidity and trading for investors.
Focused Biotech Exposure
The fund offers pure exposure to the biotechnology and health care space, which can benefit if the sector performs well.
Recent Short-Term Strength
The ETF has shown strong performance over the past month, suggesting improving momentum despite recent volatility.
Negative Factors
High Expense Ratio
The fund charges a relatively high fee, which can eat into long-term returns compared with lower-cost ETFs.
Single-Sector Concentration
With all assets in the health care and biotechnology sector, the ETF is highly sensitive to downturns in this single industry.
Weakness in Several Top Holdings
Many of the largest positions have shown weak year-to-date performance, which can drag on the fund’s overall results.
FBT vs. SPDR S&P 500 ETF (SPY)
AUM2.80B
RegionNorth America
Expense Ratio0.55%
Beta0.71
IssuerFirst Trust
Inception DateJun 19, 2006
Dividend YieldN/A
Asset ClassEquity
Index TrackedNYSE Arca Biotechnology Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume120,666
30 Day Avg. Volume61,432
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
277.84Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering30
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
FBT Summary
FBT is an exchange-traded fund that follows the NYSE Arca Biotechnology Index, focusing on U.S. biotech companies within the health care sector. It holds firms working on advanced drug development, genetics, and medical testing, including well-known names like BioNTech and Illumina. Someone might invest in FBT to seek long-term growth from breakthroughs in medicine while spreading their money across many biotech stocks instead of picking just one. However, biotech shares can be very volatile, so the value of this ETF can rise and fall sharply with news about drug trials, regulations, and the overall market.
How much will it cost me?The expense ratio for the First Trust NYSE Arca Biotechnology Index Fund (FBT) is 0.54%, which means you’ll pay $5.40 per year for every $1,000 invested. This is higher than average because the fund is actively managed, focusing on a niche sector like biotechnology that requires specialized research and expertise.
What would affect this ETF?The First Trust NYSE Arca Biotechnology Index Fund (FBT) could benefit from advancements in biotechnology and increased demand for innovative medical solutions, especially as the U.S. health care sector continues to grow. However, it may face challenges from regulatory changes, high research costs, or broader economic downturns that could impact funding and investor sentiment in the biotech industry.
FBT Top 10 Holdings
FBT is very much a biotech story, with all its heavy hitters rooted in the U.S. health care lab scene. Corcept Therapeutics and Alkermes are doing the heavy lifting, with rising share prices and solid fundamentals giving the fund a healthy pulse. Veracyte and Krystal Biotech are also climbing, adding momentum but with valuations that leave little room for error. On the flip side, NeoGenomics and Natera look more mixed, with ongoing profitability issues that occasionally trip up performance, reminding investors that this is a high-reward, high-volatility corner of the market.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Corcept Therapeutics | 5.63% | $161.93M | $8.58B | 7.31% | 76 Outperform | |
| NeoGenomics | 5.16% | $148.30M | $1.45B | 59.77% | 55 Neutral | |
| Veracyte | 4.81% | $138.12M | $4.28B | 99.14% | 76 Outperform | |
| Bruker | 4.29% | $123.36M | $8.71B | 45.96% | 63 Neutral | |
| Alkermes | 4.28% | $123.08M | $7.50B | 57.28% | 80 Outperform | |
| Illumina | 4.08% | $117.37M | $24.50B | 78.10% | 71 Outperform | |
| Krystal Biotech | 3.79% | $108.94M | $10.26B | 149.01% | 80 Outperform | |
| Natera | 3.79% | $108.86M | $33.14B | 34.30% | 73 Outperform | |
| Axsome Therapeutics | 3.59% | $103.19M | $12.89B | 143.83% | 57 Neutral | |
| Neurocrine | 3.54% | $101.71M | $15.92B | 28.47% | 80 Outperform |
FBT Technical Analysis
Positive
―
Price Trends
221.70
Positive
212.01
Positive
206.89
Positive
Market Momentum
9.82
Negative
83.13
Negative
97.33
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FBT, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 236.61, equal to the 50-day MA of 221.70, and equal to the 200-day MA of 206.89, indicating a bullish trend. The MACD of 9.82 indicates Negative momentum. The RSI at 83.13 is Negative, neither overbought nor oversold. The STOCH value of 97.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FBT.
FBT Peer Comparison
Comparison Results
Performance Comparison
FBT
First Trust NYSE Arca Biotechnology Index Fund
255.60
91.27
55.54%
IBB
iShares Biotechnology ETF
―
―
―
FHLC
Fidelity MSCI Health Care Index ETF
―
―
―
IYH
iShares U.S. Healthcare ETF
―
―
―
IHI
iShares U.S. Medical Devices ETF
―
―
―
IHF
iShares U.S. Healthcare Providers ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents